Ascendis Pharma A/S
NASDAQ:ASND · NASDAQ Global Select
-$0.05 today
Vol 0.89M · Avg 0.64M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ASND · Revenue to Net Income
Key Ratios
Analysis
$867.5M of revenue converted into $506.6M of net income for the selected period. Gross margin is 87.5% and net margin is 47.1%, showing how much revenue survives after costs and taxes. EPS is $7.55, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $691.7M +90.2% | $363.6M +36.3% | $266.7M +421.2% | $51.2M +557.9% | $7.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $103.2M +133.1% | $44.3M -0.3% | $44.4M +265.8% | $12.1M +244.5% | $3.5M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $588.5M +84.3% | $319.4M +43.7% | $222.3M +469.5% | $39.0M +817.4% | $4.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 85.1% -2.7pp | 87.8% +4.5pp | 83.4% +7.1pp | 76.3% +21.6pp | 54.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $283.5M -7.7% | $307.0M -25.7% | $413.5M +8.9% | $379.6M +28.3% | $295.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $435.9M +53.2% | $284.5M +10.0% | $258.8M +19.9% | $215.8M +34.8% | $160.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $719.4M +20.3% | $598.1M -11.8% | $677.9M +12.8% | $600.9M +31.8% | $456.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $17.0M -4.0% | $17.7M -6.3% | $18.9M +8.0% | $17.5M +13.8% | $15.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$109.8M +62.1% | -$290.0M +29.5% | -$411.2M +22.3% | -$529.2M -45.1% | -$364.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -15.9% +63.9pp | -79.8% +74.4pp | -154.2% +879.9pp | -1034.1% +3654.0pp | -4688.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$130.9M +53.0% | -$278.8M +38.8% | -$455.5M +18.9% | -$561.8M -24.4% | -$451.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -18.9% +57.7pp | -76.7% +94.1pp | -170.8% +927.1pp | -1097.9% +4710.7pp | -5808.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $14.7M +2.3% | $14.4M -14.8% | $16.9M +127.0% | $7.4M +973.1% | $692.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $77.5M +18.3% | $65.5M +48.7% | $44.1M +43.6% | $30.7M +684.5% | $3.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$73.4M +22.3% | -$94.5M -407.9% | -$18.6M -16.2% | -$16.0M -123.6% | $67.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$204.3M +45.3% | -$373.2M +21.3% | -$474.1M +17.9% | -$577.8M -50.5% | -$383.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -29.5% +73.1pp | -102.6% +75.1pp | -177.8% +951.4pp | -1129.1% +3807.2pp | -4936.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $14.8M +205.1% | $4.8M -33.7% | $7.3M +35.8% | $5.4M +1565.1% | -$367.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$219.0M +42.1% | -$378.1M +21.5% | -$481.4M +17.4% | -$583.2M -52.0% | -$383.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -31.7% +72.3pp | -104.0% +76.5pp | -180.5% +959.1pp | -1139.6% +3791.9pp | -4931.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 +44.6% | -$7 +23.6% | -$9 +17.8% | -$10 -48.6% | -$7 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 +44.6% | -$7 +23.6% | -$9 +17.8% | -$10 -48.6% | -$7 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $60.6M +4.7% | $57.9M +2.9% | $56.3M +0.4% | $56.1M +2.4% | $54.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $60.6M +4.7% | $57.9M +2.9% | $56.3M +0.4% | $56.1M +2.4% | $54.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Moderna, Inc.
NASDAQ:MRNA
$24.52B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Guardant Health, Inc.
NASDAQ:GH
$17.12B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.20B
Exelixis, Inc.
NASDAQ:EXEL
$13.18B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.28B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.52B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.91B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.63B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ASND generate?
Ascendis Pharma A/S (ASND) reported $691.71M of revenue in fiscal 2025.
Is ASND profitable?
Ascendis Pharma A/S (ASND) reported -$219,034,140.00 of net income, with a net margin of -31.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.